Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CVS Expands Formulary Exclusions In 2017, Express Scripts’ Tally Unchanged

Executive Summary

National formulary exclusions continue in 2017, with CVS aggressively expanding its list of “not covered” drugs. Express Scripts currently excludes slightly fewer drugs than last year but may still add to its list.

You may also be interested in...



Will Epoetin Biosimilar Serve As Non-Medical Switching Case Study?

Analysts expect potential broad uptake of biosimilars in chronic kidney disease treated at dialysis centers, which could lead to patients being switched off Amgen's Epogen.

Will Epoetin Biosimilar Serve As Non-Medical Switching Case Study?

Analysts expect potential broad uptake of biosimilars in chronic kidney disease treated at dialysis centers, which could lead to patients being switched off Amgen's Epogen.

3Q Pharma Results Preview: Novartis, Merck, Lilly, Bayer, GSK, Bristol, Amgen, Sanofi

Johnson & Johnson and Roche launched the big pharma quarterly reporting season. Next up are Novartis, Lilly, Merck, Bayer, GSK, Bristol-Myers Squibb, Amgen and Sanofi. Scrip offers some key points to watch for.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC097051

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel